Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

NZNanfang ZhuoXLXiangjie LinPCPengfei Chai

Discussion

Loading...

Member takes

Overview

Bispecific antibody demonstrates increased T cell activation in AML, suggesting improved survival outcomes.

Key Points

  • The aim is to evaluate the efficacy and safety of a CD84-CD3 bispecific antibody in treating Acute Myeloid Leukemia.
  • Generated nine CD84-CD3 bispecific antibodies, selecting candidates based on expression yield and purity.
  • Evaluated T-cell activation and cytotoxicity against AML cell lines and patient blasts at various antibody concentrations.
  • Conducted in vivo studies using xenografted mice to assess tumor burden and survival after treatment.
  • CD84-CD3 bispecific antibody showed significant T cell activation and cytokine release, enhancing anti-leukemic activity.
  • In vivo treatments with the bispecific antibodies significantly extended survival compared to control groups.
  • Evidence of selective targeting against AML cells was observed, sparing healthy donor cells.

Cite This Study

Zhuo et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deechttps://doi.org/10.1182/blood-2025-2355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancement of CD117-targeted bispecific T-cell engagement by CD33-targeted bispecific T-cell co-stimulation in acute myeloid leukemia2026
  2. 2Abstract 6712: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of LILRB4 positive leukemia2024
  3. 3Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells2024 · 4 citations
  4. 4CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy2026 · 1 citations
  5. 5A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model2025